Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 2
1990 1
1992 1
1993 1
1994 1
1995 1
2003 1
2008 1
2010 1
2011 4
2012 1
2015 3
2017 2
2018 1
2019 1
2020 1
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Sensitization and development of tolerance via the gut.
Hanson LA, Telemo E, Wiedermann U, Dahlman A, Saalman R, Ahlstedt S, Friman V, Holmgren J, Czerkinsky C, Dahlgren U. Hanson LA, et al. Among authors: dahlman a. Pediatr Allergy Immunol. 1993;4(3 Suppl):16-20. doi: 10.1111/j.1399-3038.1993.tb00326.x. Pediatr Allergy Immunol. 1993. PMID: 8348258 Review. No abstract available.
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH, Fritzell S, Miller R, Werchau D, Van Citters D, Nilsson A, Misher L, Ljung L, Bader R, Deronic A, Chunyk AG, Schultz L, Varas LA, Rose N, Håkansson M, Gross J, Furebring C, Pavlik P, Sundstedt A, Veitonmäki N, Ramos HJ, Säll A, Dahlman A, Bienvenue D, von Schantz L, McMahan CJ, Askmyr M, Hernandez-Hoyos G, Ellmark P. Nelson MH, et al. Among authors: dahlman a. Mol Cancer Ther. 2023 Jan 3;22(1):89-101. doi: 10.1158/1535-7163.MCT-22-0395. Mol Cancer Ther. 2023. PMID: 36343381 Free PMC article.
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.
Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M. Poulsen TT, et al. Among authors: dahlman a. Clin Cancer Res. 2017 Oct 1;23(19):5923-5935. doi: 10.1158/1078-0432.CCR-17-0782. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679766
External communication of automated shuttles: Results, experiences, and lessons learned from three European long-term research projects.
Mirnig AG, Gärtner M, Fröhlich P, Wallner V, Dahlman AS, Anund A, Pokorny P, Hagenzieker M, Bjørnskau T, Aasvik O, Demir C, Sypniewski J. Mirnig AG, et al. Among authors: dahlman as. Front Robot AI. 2022 Oct 26;9:949135. doi: 10.3389/frobt.2022.949135. eCollection 2022. Front Robot AI. 2022. PMID: 36388257 Free PMC article.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P. Kvarnhammar AM, et al. Among authors: dahlman a. J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8. J Immunother Cancer. 2019. PMID: 30975201 Free PMC article.
32 results